Novo Nordisk and AWS Forge Alliance to Enhance Drug Discovery with AI

Novo Nordisk and Amazon Web Services (AWS) have announced a strategic partnership designed to accelerate drug discovery and modernize Novo Nordisk’s operations through advanced AI and cloud technologies. They have established a co-innovation hub in London, where AWS engineers and specialists will collaborate with Novo Nordisk's research teams to enhance productivity and streamline the journey from drug target identification to the first human dose.

“Partnering with AWS is about making AI a driver of innovation across Novo Nordisk,” said Mike Doustdar, president and CEO of Novo Nordisk. “By combining our scientific expertise with AWS’ tools and purpose-built services for the life sciences industry, while also creating a dedicated co-innovation hub within our existing facility in London, we are accelerating discovery and developing responsible AI solutions that will create real progress for people living with serious chronic diseases.”

As part of the agreement, AWS will serve as Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging Novo Nordisk's extensive knowledge in chronic diseases alongside AWS's advanced cloud and AI services. This collaboration has already yielded measurable results, such as decreased clinical documentation time and increased productivity for over 25,000 employees. The partnership is set to lay the groundwork for developing new therapies globally, utilizing tools like Amazon Bio Discovery and Amazon Bedrock to expedite drug design and connect diverse datasets.

"Every part of our work with Novo Nordisk comes back to one thing: getting the right medicine to patients, faster," said Matt Garman, CEO, AWS. "Novo Nordisk has chosen AWS as their strategic AI partner to fundamentally change how medicines are discovered and developed using services such as Amazon Bio Discovery and Amazon Bedrock. We’re excited to partner with Novo Nordisk so that these technologies, AWS Forward Deployed Engineers, and Novo Nordisk’s industry-leading science teams can help compress drug discovery timelines, securely process complex datasets, and scale findings across therapeutic areas.”

Additionally, Novo Nordisk engages with various Amazon businesses, including Amazon Pharmacy and Amazon One Medical, to enhance how new therapies are marketed and delivered to patients. Novo Nordisk, founded in 1923 and based in Denmark, is dedicated to combating serious chronic diseases, primarily focusing on diabetes, through scientific advancements and broadening access to its medications. The company employs approximately 66,700 staff across 80 countries, marketing its products in around 170 nations. For more information, visit novonordisk.com.